Long-Term Follow-up: Phase I/II Clinical Study to Evaluate the Safety and Efficacy of the Infusion of RP-L102
← catalyst calendarNCT07527975 · readout ≤ 4,303 d
Sponsored by Rocket Pharmaceuticals Inc. (industry) · RCKT — their whole pipeline →.
Phase
—
Status
Enrolling by invitation
Study type
Observational
Enrollment
14estimated
Sites
3
Countries
Spain, United Kingdom, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-02-01 | actual | When the study began enrolling |
| Primary completion | May 2038 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | May 2038 | estimated | The whole study's end, after follow-up |
| First posted | 2026-04-14 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-14 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Fanconi Anemia
Intervention
- Biological: RP-L102
Primary outcomes
what the primary-completion date above is the date OFSurvival in patients treated in the RP-L102 parent studies (RP-L102-0418, RP-L102-0319, RP-L102-0118).
measured From infusion in parent study to 15-years post-infusion.
Long term safety
measured From infusion in parent study to 15-years post-infusion.
Long-term persistence of the therapeutic LV (provirus) in hematopoietic cells in the bone marrow (BM) and blood.
measured From infusion in parent study to 15-years post-infusion.
Long-term clonality patterns.
measured From infusion in parent study to 15-years post-infusion.
Replication-competent lentivirus (RCL) in serum and peripheral blood cells.
measured From infusion in parent study to 15-years post-infusion.
Long-term stability and normalization of blood counts.
measured From infusion in parent study to 15-years post-infusion.
Phenotypic correction of BM and peripheral blood cells
measured From infusion in parent study to 15-years post-infusion.
Incidence of hematologic malignancies and solid organ tumors.
measured From infusion in parent study to 15-years post-infusion.
Permalink · RCKT's whole pipeline · Catalyst calendar · Every registered study · What changed